Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Clostridium Difficle Colitis Clear all

Conditions: Clostridium Difficile
Interventions: Stool; Biological
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions: tolevamer potassium-sodium (GT267-004); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 99
States / cities: Phoenix, Arizona • Rogers, Arkansas • Burbank, California + 81 more

Conditions: Clostridium Difficile Infection
Interventions: Bismuth Subsalicylate, standard antibiotic therapy; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions: Not listed
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Baltimore, Maryland • Houston, Texas

Conditions: Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions: RBX2660; Drug
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 46
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more

Conditions: Antibiotic-Associated Diarrhea, Clostridium Difficile
Interventions: loperamide, placebo; Drug
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Moderate Clostridium Difficile Infection
Interventions: LFF571, Vancomycin (POC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more

Conditions: Gastrointestinal Hemorrhage, Clostridium Difficile Colitis
Interventions: Pantoprazole 40 mg IV daily and tube feed., Placebo and tube feed; Drug · Other
Lead sponsor: Mohamed Saad; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Clostridium Difficile Colitis
Interventions: Standard Vancomycin, Extended Vancomycin; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Clostridium Difficile Infection (CDI)
Interventions: RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence); Drug
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 60
States / cities: Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more

Conditions: Dysbiosis, Clostridium Difficile, Pet-Human Bonding, Antibiotic-Associated Colitis
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Clostridium Difficile Colitis
Interventions: Small Bowel Transit Study; Radiation
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Gastroenteritis, Infectious Colitis
Interventions: Not listed
Lead sponsor: Luminex Corporation; Industry
Eligibility: Not listed
Enrollment: 1,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Tampa, Florida • Indianapolis, Indiana • Albuquerque, New Mexico + 1 more

Conditions: Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions: Bezlotoxumab, Placebo, Fecal Microbiota Transplantation; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions: Vancomycin (POC), Fidaxomicin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Clostridium Difficile
Interventions: Nitazoxanide, Metronidazole; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 7
States / cities: St. Petersburg, Florida • Marietta, Georgia • Columbus, Ohio + 3 more

Conditions: Clostridium Difficile Infection, Diarrhea
Interventions: Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant), Clostridium difficile toxoids A and B (high-dose without adjuvant), Placebo: 0.9% normal saline; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 30
States / cities: Redding, California • Bristol, Connecticut • Stamford, Connecticut + 25 more

Conditions: Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions: Metronidazole; Drug
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Interventions: Bezlotoxumab; Biological
Lead sponsor: David Binion, MD; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Clostridium Difficile Infection
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Clostridium Difficile Colitis
Interventions: Ileal diversion and lavage, total abdominal colectomy; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.

Extended Treatment With Vancomycin for Clostridium Difficile Colitis

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs

Small Bowel Transit Time in Clostridium Difficile Colitis

A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Response of Clostridium Difficile Infection to Metronidazole Therapy

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Pathogenic Mechanisms in C Diff Infection and Colitis

Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis